Baiya International Group Inc. - Ordinary Shares (BIYA)

While investors chase the GLP-1 drug boom, a critical bottleneck is emerging that could reshape the entire market— liver imaging simply doesn’t scale to meet the coming demand. As metabolic dysfunction–associated steatotic liver disease (MASLD) and GLP-1 therapies continue to expand globally, ENDRA Life Sciences (NASDAQ: NDRA) is positioning its TAEUS® (Thermo-Acoustic Enhanced UltraSound) platform to address a growing constraint in clinical trials and patient care: scalable liver imaging .